Navigation Links
U.S. and European Soft Tissue Repair Device Markets Will Expand Modestly In Line With Large Hernia Repair Device Market
Date:8/14/2014

BURLINGTON, Mass., Aug. 14, 2014 /PRNewswire/ -- Decision Resources Group finds that the soft tissue repair device markets in the United States and Europe will expand slightly through 2022. These markets will be primarily affected by trends in the hernia repair device market, which brings in the most revenues. This is due to the very high incidence of hernias, favorable clinical data supporting the benefits of hernia mesh and ongoing product innovation that helps maintain pricing.

Other key findings from Decision Resources Group's coverage of the U.S. and European soft tissue repair device markets:

  • Hernia repair devices: The hernia repair device market will be supported by the adoption of premium-priced composite and proprietary synthetic mesh in the ventral and inguinal hernia indications, respectively. Particularly fast-growing products in 2013 included C. R. Bard's Ventrio Light hernia patch and Covidien's Parietex Optimized composite mesh.
  • PFR devices and vaginal slings: The pelvic floor reconstruction (PFR) device and vaginal sling markets declined in 2013 due to warnings and publicity about the potential for adverse patient events, although they will recover slowly through 2022. In general, these soft tissue repair device markets have been plagued by lawsuits, and manufacturers are under enormous pressure to more stringently test safety.
  • Male slings, staple line reinforcement devices and dural repair devices: The male sling and staple line reinforcement device markets (included in U.S. coverage only) as well as the dural repair device market (included in European coverage only) will exhibit moderate growth through 2022 as mesh products are increasingly accepted for the relevant indications.

Comments from Decision Resources Group Senior Analyst Manya Aggarwal:

  • "In the U.S. hernia repair fixation device market, adoption of premium-priced absorbable tackers, which cause less pain and fewer adhesions, will grow at the expense of nonabsorbable tackers. Absorbable products will be primarily used in ventral hernia repair, where clinical evidence is stronger."

Comments from Decision Resources Group Senior Analyst Lexie Code:

  • "Because of the widespread negative publicity in the PFR device market, C. R. Bard and Ethicon have both withdrawn products, and remaining large competitors have not been concentrating on this space. As a result, some smaller local competitors have gained share, but these independents are also bearing the burden of convincing doctors and women to consider these procedures again, making the turnaround quite a slow process."

Additional Resources:

  • Manya Aggarwal and Lexie Code have written Medtech 360 reports on this subject entitled US Markets for Soft Tissue Repair Devices 2014 and European Markets for Soft Tissue Repair Devices, respectively.
  • Decision Resources Group's Marketrack, which provides market share data by brand for the U.S. soft tissue repair device market, can be found here.

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group 
Christopher Comfort 
781-993-2597  
ccomfort@dresourcesgroup.com

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO


'/>"/>
SOURCE Decision Resources Group
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
2. Biodels Intellectual Property Position Strengthened for Ultra-Rapid-Acting Insulin Programs by Notice of Intent to Grant from European Patent Office
3. Marken Acquires European Kit Building Operation From LabCorp Clinical Trials
4. Blood Disorders: European Hematologists Gather in Amsterdam, June 14-17, 2012
5. Mylan Launches Generic Lipitor® in Five European Countries
6. European Thrombosis Therapeutics Market is Experiencing an Urgent Need for Enhanced Products, Says Frost & Sullivan
7. Bristol-Myers Squibb to Present New Data on ORENCIA(R)? (abatacept) at the European League Against Rheumatism (EULAR) 2012 Congress
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Study Results of Novocures NovoTTF™ Pivotal Phase 3 Trial Published in European Journal of Cancer
10. Cardiac Dimensions® Announces Publication of TITAN Clinical Trial Data in European Journal of Heart Failure
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Oasmia ... developer of a new generation of drugs within ... survival results for Paclical/Apealea in the Phase III ... with epithelial ovarian cancer. These preliminary results showed ... combination with carboplatin versus Taxol in combination with ...
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
(Date:4/26/2016)... 26, 2016 US demand for infection ... 4.9 percent annually to $27.6 billion in 2020.  ... to decrease rates of healthcare-associated infections (HAIs) will ... and services.  Although declining, the overall rate of ... levels set by the CDC.  Recent statistics indicate ...
Breaking Medicine Technology:
(Date:4/28/2016)... (PRWEB) , ... April 29, 2016 , ... Monthly subscription ... products on the market. They recently reviewed the ZEN BOX , the aromatherapy ... are two single essential oils (like lavender or frankincense) and one Zen Blend (like ...
(Date:4/28/2016)... ... April 28, 2016 , ... Sanford Health’s ... week. A group of researchers and leaders from Sanford Health were selected to ... and Its Cultural Impact ” and receive the 2016 Pontifical Key Innovation Award ...
(Date:4/28/2016)... ... 2016 , ... CastCoverz!, America’s #1 trusted brand for cast ... waterproof cast protector . As the largest one-stop, orthopedic shop, CastCoverz! offers ... night, weatherproof and waterproof covers for most orthopedic devices, including but not limited ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... announces today the open availability of a new CDISC standard, Clinical Trial ... registering clinical trials. This innovative standard will make it possible to build ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity Health, one of ... leading force in the fight to reduce tobacco use and its deadly toll, ... help reduce tobacco use. The initiative brings together two organizations committed to achieving ...
Breaking Medicine News(10 mins):